Laurent Hennequin

4.2k total citations · 1 hit paper
52 papers, 2.7k citations indexed

About

Laurent Hennequin is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Laurent Hennequin has authored 52 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 27 papers in Organic Chemistry and 21 papers in Oncology. Recurrent topics in Laurent Hennequin's work include Quinazolinone synthesis and applications (18 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and HER2/EGFR in Cancer Research (10 papers). Laurent Hennequin is often cited by papers focused on Quinazolinone synthesis and applications (18 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and HER2/EGFR in Cancer Research (10 papers). Laurent Hennequin collaborates with scholars based in France, United Kingdom and United States. Laurent Hennequin's co-authors include Jon Curwen, Stephen R. Wedge, Jane Kendrew, Patrick A. Plé, Donald Ogilvie, Elaine S. E. Stokes, Andrew P. Thomas, Michael Dukes, Christine Lambert‐van der Brempt and P.F. Wadsworth and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Laurent Hennequin

52 papers receiving 2.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 702 citations Stephen R. Wedge, Donald Ogilvie et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurent Hennequin France	22	1.5k	973	773	500	341	52	2.7k
Jon Curwen United Kingdom	20	1.5k 1.0×	1.0k 1.0×	491 0.6×	634 1.3×	406 1.2×	31	2.7k
Gerhard Siemeister Germany	32	2.2k 1.5×	959 1.0×	430 0.6×	411 0.8×	594 1.7×	68	3.3k
Jane Kendrew United Kingdom	22	1.5k 1.0×	1.1k 1.1×	295 0.4×	638 1.3×	561 1.6×	33	2.7k
Jennifer L. Stamos United States	14	2.2k 1.5×	788 0.8×	566 0.7×	370 0.7×	210 0.6×	17	3.3k
Richard Kendall United States	24	1.8k 1.2×	837 0.9×	315 0.4×	268 0.5×	476 1.4×	43	3.0k
Randall Schreck United States	9	1.5k 1.0×	686 0.7×	226 0.3×	318 0.6×	469 1.4×	13	2.3k
Melanie Valenti United Kingdom	30	1.7k 1.1×	1.1k 1.1×	383 0.5×	197 0.4×	302 0.9×	61	2.6k
Carolyn Discafani United States	23	1.4k 0.9×	1.4k 1.4×	872 1.1×	569 1.1×	223 0.7×	30	3.0k
Josef Brueggen Switzerland	10	1.8k 1.2×	633 0.7×	188 0.2×	348 0.7×	381 1.1×	14	2.4k
Cinzia Lanzi Italy	33	1.5k 1.0×	895 0.9×	248 0.3×	249 0.5×	317 0.9×	73	2.4k

Countries citing papers authored by Laurent Hennequin

Since Specialization

Citations

This map shows the geographic impact of Laurent Hennequin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Hennequin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Hennequin more than expected).

Fields of papers citing papers by Laurent Hennequin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Hennequin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Hennequin. The network helps show where Laurent Hennequin may publish in the future.

Co-authorship network of co-authors of Laurent Hennequin

This figure shows the co-authorship network connecting the top 25 collaborators of Laurent Hennequin. A scholar is included among the top collaborators of Laurent Hennequin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurent Hennequin. Laurent Hennequin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Longo, Raffaele, et al.. (2020). Renal Metastases from a Nasal Cavity Mixed Squamous Cell and Adenoid Cystic Carcinoma: A Case Report. American Journal of Case Reports. 21. e919781–e919781. 2 indexed citations

Longo, Raffaele, et al.. (2019). A paraneoplastic limbic encephalitis from an anorectal small cell neuroendocrine carcinoma: a case report. BMC Neurology. 19(1). 304–304. 3 indexed citations

Jing, Jing, Elin Säwén, Thibaud Gerfaud, et al.. (2018). Rapid and Selective Cleavage of Amide Groups at Neutral pH: Applications from Hyaluronic Acid to Small Molecules. European Journal of Organic Chemistry. 2018(23). 2995–3000. 2 indexed citations

Poulin, Patrick, et al.. (2018). Application of the Tissue Composition–Based Model to Minipig for Predicting the Volume of Distribution at Steady State and Dermis-to-Plasma Partition Coefficients of Drugs Used in the Physiologically Based Pharmacokinetics Model in Dermatology. Journal of Pharmaceutical Sciences. 108(1). 603–619. 11 indexed citations

Plastino, Francesca, et al.. (2017). Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report. American Journal of Case Reports. 18. 7–11. 20 indexed citations

Barlaam, Bernard, Judith Anderton, Peter Ballard, et al.. (2013). Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Medicinal Chemistry Letters. 4(8). 742–746. 31 indexed citations

Plé, Patrick A., Frédéric Jung, Sue Ashton, et al.. (2012). ChemInform Abstract: Discovery of AZD2932 (I), a New Quinazoline Ether Inhibitor with High Affinity for VEGFR‐2 and PDGFR Tyrosine Kinases.. ChemInform. 43(20). 1 indexed citations

Brave, Sandra R., Kirsty Ratcliffe, Zena Wilson, et al.. (2011). Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family. Molecular Cancer Therapeutics. 10(5). 861–873. 72 indexed citations

Plé, Patrick A., Frédéric Jung, Sue Ashton, et al.. (2011). Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 22(1). 262–266. 44 indexed citations

10.

Harris, Craig S., et al.. (2009). Three-point variation of a gefinitib quinazoline core. Tetrahedron Letters. 50(14). 1600–1602. 6 indexed citations

11.

Green, Tim P., Jon Curwen, Vivien N. Jacobs, et al.. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology. 3(3). 248–261. 176 indexed citations

12.

Hennequin, Laurent, Jeffrey C. Allen, Gerard Costello, et al.. (2005). The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Cancer Research. 65. 595–595. 16 indexed citations

13.

Ballard, Peter, Robert H. Bradbury, Craig S. Harris, et al.. (2005). Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorganic & Medicinal Chemistry Letters. 16(6). 1633–1637. 31 indexed citations

14.

Green, Tim, Laurent Hennequin, Patrick A. Plé, et al.. (2005). Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530. 65. 1463–1463. 7 indexed citations

15.

Wedge, Stephen R., Jane Kendrew, Jon Curwen, et al.. (2004). The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo. Cancer Research. 64. 1052–1052. 7 indexed citations

16.

Plé, Patrick A., Tim P. Green, Laurent Hennequin, et al.. (2004). Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src. Journal of Medicinal Chemistry. 47(4). 871–887. 139 indexed citations

17.

Whittles, C.E., Tristan Pocock, Stephen R. Wedge, et al.. (2002). ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity. Microcirculation. 9(6). 513–522. 5 indexed citations

18.

Bourcier, Christine, Sandrine Marchetti, Clotilde Gimond, et al.. (2002). Complete Structure of an Increasing Capillary Permeability Protein (ICPP) Purified from Vipera lebetina Venom. Journal of Biological Chemistry. 277(33). 29992–29998. 34 indexed citations

19.

Bruneau, Pierrick, et al.. (1990). Synthesis and structure elucidation of new spirocephams. Tetrahedron Letters. 31(49). 7141–7144. 1 indexed citations

20.

Duhamel, Pierre, et al.. (1985). Une méthode simple et efficace de préparation de composés dicarbonylés-1,5. Tetrahedron Letters. 26(50). 6201–6204. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact